Evidence map›Paper›PMID 40599278›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025

[Effect of ADAM12, S100A8, and Serum Tumor Markers on Chemotherapy Outcomes and Prognosis in Patients With Triple-Negative Breast Cancer].

Zifang Qin, Xu Wang, Zhaoxia Niu, Ruoxia Jiang, Lin Zhang

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zifang Qin（ 450003） Department of Pathophysiology, Henan Medical College, Zhengzhou 450003, China.
Xu Wang（ 450003） Department of Pathophysiology, Henan Medical College, Zhengzhou 450003, China.
Zhaoxia Niu（ 450003） Department of Pathophysiology, Henan Medical College, Zhengzhou 450003, China.
Ruoxia Jiang（ 450003） Department of Pathophysiology, Henan Medical College, Zhengzhou 450003, China.
Lin Zhang（ 450003） Department of Pathophysiology, Henan Medical College, Zhengzhou 450003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the influence of a disintegrin and metalloproteinase 12 (ADAM12), S100 calcium binding protein A8 (S100A8), and serum tumor markers on chemotherapy outcomes and prognosis in patients with triple-negative breast cancer. Methods: A totla of 300 patients with breast cancer admitted between January 2020 and January 2021 were included. Based on pathological immunohistochemistry findings, the patients were divided into a triple-negative group ( Results: The protein expression levels of ADAM12 and S100A8 in cancer tissues from the triple-negative group were higher than those in the non-triple-negative group ( Conclusion: ADAM12 and S100A8 protein expression levels in triple-negative breast cancer tissues are higher than those in non- triple-negative breast cancer tissues. Serum tumor markers and ADAM12 and S100A8 protein expression levels (in both serum and tumor tissues) affect the chemotherapy outcomes and prognosis of triple-negative breast cancer patients, among which the expression levels of ADAM12 and S100A8 proteins in tumor tissues can serve as predictors of patient prognosis.

Indexed as

ADAM12 ProteinBiomarkers, TumorMembrane ProteinsTriple Negative Breast NeoplasmsAdultAgedCA-125 AntigenCalgranulin AFemaleHumansMiddle AgedPrognosisADAM12 ProteinADAM12 protein, humanBiomarkers, TumorCA-125 AntigenCalgranulin AMembrane ProteinsS100A8 protein, humanA disintegrin and metalloproteinase 12S100 calcium binding protein A8Triple-negative breast cancerTumor markers

Identifiers

PMID40599278
PMCPMC12207044

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.